2021
DOI: 10.1007/7854_2020_202
|View full text |Cite
|
Sign up to set email alerts
|

Innovations in the Delivery of Exposure and Response Prevention for Obsessive-Compulsive Disorder

Abstract: Obsessive-Compulsive Disorder is an important cause of global healthrelated disability. In the last several decades, exposure and response prevention (EX/RP) has emerged as one of the most evidence-based treatments for adult and pediatric OCD. Recommended as a first-line treatment in practice guidelines for OCD, EX/RP, when expertly delivered, can be superior to serotonin reuptake

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
2
1
1

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(2 citation statements)
references
References 148 publications
0
2
0
Order By: Relevance
“…By contrast, recent research in our laboratory found that chronic THC administration delayed SID acquisition, and acute THC administration reduced SID only in rats that had previously experienced a chronic treatment with the same drug, suggesting a sensitization-like effect (Fuentes-Verdugo et al 2022). Clinical trials have shown that cannabis users with OCD reported that cannabinoids mitigated their symptoms, including obsessions and compulsions (Müller-Vahl 2013;Schindler et al 2008;Szejko et al 2020;Patel et al 2021), and another recent study reported that nabilone, a synthetic cannabinoid with similar effects to THC, alleviated OCD severity in combination with exposure and response prevention therapy, nearly doubling the effect compared to exposure and response prevention alone (Kayser et al 2020). All this evidence points to ECS as a potential target for novel medications aiming OCD symptoms.…”
Section: Introductionmentioning
confidence: 80%
“…By contrast, recent research in our laboratory found that chronic THC administration delayed SID acquisition, and acute THC administration reduced SID only in rats that had previously experienced a chronic treatment with the same drug, suggesting a sensitization-like effect (Fuentes-Verdugo et al 2022). Clinical trials have shown that cannabis users with OCD reported that cannabinoids mitigated their symptoms, including obsessions and compulsions (Müller-Vahl 2013;Schindler et al 2008;Szejko et al 2020;Patel et al 2021), and another recent study reported that nabilone, a synthetic cannabinoid with similar effects to THC, alleviated OCD severity in combination with exposure and response prevention therapy, nearly doubling the effect compared to exposure and response prevention alone (Kayser et al 2020). All this evidence points to ECS as a potential target for novel medications aiming OCD symptoms.…”
Section: Introductionmentioning
confidence: 80%
“…If an imbalance between goal-directed and habitual control play a central role in OCS/OCD, where compulsive behaviors are thought to be controlled by habitual systems, then breaking these compulsive habitual behaviors and restoring goal-directed control is likely important for intervention efforts (Kalanthroff et al, 2018). The most used technique to treat OCD is Cognitive Behavior Therapy (CBT) which uses exposure and response techniques (see Patel et al, 2021). This technique involves teaching individuals to confront situations that result in obsessions and inhibit compulsive behaviors.…”
Section: Ocs/ocd and The Habit Hypothesismentioning
confidence: 99%